Bioventus Balance Sheet
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bioventus financial position
At the end of fiscal 2025, Bioventus reported total assets of $683.6 million, down 6.1% from a year earlier against total liabilities of $455.1 million. Shareholders' equity stood at $184.1 million, or 26.9% of assets. The company held $51.2 million in cash and equivalents against $294.0 million of debt, a net debt position of $242.7 million.
The current ratio (current assets divided by current liabilities) was 1.70, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.60.
Summary generated from market data by MetaCap's automated system. Methodology
Bioventus balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 51.24M | 41.58M | 36.96M | 30.19M | 43.93M | 86.84M | 64.52M |
| Receivables | 128.30M | 127.39M | 122.79M | 136.29M | 124.96M | 88.28M | — |
| Inventory | 82.24M | 92.47M | 91.33M | 84.77M | 61.69M | 29.12M | — |
| Total Current Assets | 272.84M | 275.61M | 268.00M | 272.57M | 263.10M | 211.79M | — |
| Property, Plant & Equipment | 21.90M | 27.01M | 36.60M | 27.65M | 22.98M | 6.88M | — |
| Goodwill | 7.46M | 7.46M | 7.46M | 7.46M | 147.62M | 49.80M | — |
| Intangible Assets | 368.42M | 404.73M | 482.35M | 639.85M | 695.19M | 191.65M | — |
| Long-Term Investments | 2.29M | 1.89M | 3.14M | 2.62M | 29.29M | 19.38M | — |
| Total Assets | 683.56M | 727.96M | 810.91M | 1.37B | 1.23B | 494.47M | — |
| Accounts Payable | 10.93M | 23.69M | 23.04M | 36.70M | 16.91M | 4.42M | — |
| Short-Term Debt | 15.00M | 27.34M | 27.85M | 33.06M | 18.04M | 15.00M | — |
| Total Current Liabilities | 160.38M | 210.40M | 175.50M | 304.02M | 180.86M | 122.59M | — |
| Long-Term Debt | 278.95M | 308.29M | 367.00M | 385.01M | 339.64M | 173.38M | — |
| Total Liabilities | 455.11M | 542.35M | 589.79M | 960.43M | 618.21M | 350.31M | — |
| Shareholders' Equity | 184.10M | 147.94M | 173.59M | 325.24M | 458.92M | — | — |
| Retained Earnings | -334.93M | -357.66M | -321.54M | -165.31M | -6.60M | — | — |
| Total Debt | 293.95M | 335.63M | 394.85M | 418.07M | 357.68M | 188.38M | — |
| Net Cash (Debt) | -242.71M | -294.05M | -357.88M | -387.88M | -313.75M | -101.54M | 64.52M |
This table shows 7 annual periods of Bioventus's balance sheet, from FY 2025 back to FY 2019, across 18 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow BVS's reporting calendar. What is a balance sheet?